SLXN (Silexion Therapeutics Corp) Wutah bathi resik saben saham ing taun iki

High dependence on third-party CROs/CMOs creates market volatility, causing the annual EPS growth metric to exhibit sharp fluctuations, with the indicator reaching the level of 47.90. Silexion Therapeutics Corp (SLXN) ensures stability through partnerships with biotech centers focused on combating KRAS mutations. The business is protected by strict FDA regulations and a patent monopoly on RNA interference, which create insurmountable barriers for competitors.
Rincian metrik keuangan lan pasar Silexion Therapeutics Corp. (SLXN)

Silexion Therapeutics Corp (SLXN) development of innovative RNA drugs targeting KRAS mutations makes the company dependent on the efficiency of investments in clinical trials. The eps_yy_co metric measures the annual dynamics of net income per share, reflecting the actual speed of capital scaling by comparing current and prior periods. The current EPS YoY change level is 47.90, allowing investors to assess the fundamental stability of the business and the risks of asset overvaluation.